Novavax Stock Is On Deal With SK Bioscience
The business is adding into the already-massive manufacturing capability it's lined up for the COVID-19 vaccine candidate.
Word of the deal comes on the heels of important global distribution agreements Novavax signed weekly.
While the magnitude of this SK Bioscience deal wasn't revealed, Novavax has lined up sufficient production capacity to make nearly 3 billion doses of its vaccine in 2021. Binnopharm has stated that it could only create 1.5 million doses of its vaccine each year.
The statement that the Russian vaccine offender was approved to be used in its own housing routed COVID-19 vaccine stocks tumbling this week. This sell-off was quite likely an overreaction, however, given the limited production capability available for generating this vaccine, along with the deficiency of trial information that could reveal whether it functions well enough to warrant its acceptance.
For the calendar year, Novavax inventory remains up by over 3,200%.